Lipocine (LPCN) Non-Current Debt (2018 - 2021)
Lipocine's (LPCN) quarterly Non-Current Debt came in at $1.7 million in Q4 2021, down 26.14% YoY from $2.3 million in Q4 2020, and down 33.32% on a QoQ basis from $2.5 million in Q3 2021.
Lipocine (LPCN) Non-Current Debt (2018 - 2021) Analysis & Trends
Lipocine (LPCN) has 4 years of Non-Current Debt data on file, last reported at $1.7 million in Q4 2021.
- Quarterly Non-Current Debt fell 26.14% year-over-year to $1.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.7 million (down 26.14% YoY) and the FY2021 annual result came in at $1.7 million, down 26.14% from the prior year.
- Non-Current Debt declined to $1.7 million in Q4 2021, from $2.5 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $10.0 million in Q1 2018 to a low of $1.4 million in Q1 2021.
- A 4-year average of $5.3 million and a median of $4.6 million in 2019 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2019 — Non-Current Debt retreated 8.33% — and 2021, when it plunged 69.23%.
- Tracing LPCN's Non-Current Debt over 4 years: stood at $6.9 million in 2018, then sank by 44.93% to $3.8 million in 2019, then plunged by 40.83% to $2.3 million in 2020, then retreated by 26.14% to $1.7 million in 2021.
- The last three Non-Current Debt figures came in at $1.7 million (Q4 2021), $2.5 million (Q3 2021), and $1.4 million (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.67 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 1.44 Mn |
| Dec 31, 2020 | 2.26 Mn |
| Sep 30, 2020 | 3.15 Mn |
| Jun 30, 2020 | 4.00 Mn |
| Mar 31, 2020 | 4.69 Mn |
| Dec 31, 2019 | 3.81 Mn |
| Sep 30, 2019 | 4.60 Mn |
| Jun 30, 2019 | 5.38 Mn |
| Mar 31, 2019 | 9.17 Mn |
| Dec 31, 2018 | 6.93 Mn |
| Sep 30, 2018 | 10.00 Mn |
| Jun 30, 2018 | 10.00 Mn |
| Mar 31, 2018 | 10.00 Mn |